Muller, AG, Sarker, SD, Fatokun, AA and Hutcheon, GA (2022) Formulation of resveratrol into PGA-co-PDL nanoparticles increases its cytotoxic potency against lung cancer cells. RPS Pharmacy and Pharmacology Reports, 2 (1).

Preview

Text rqac007.pdf - Published Version Available under License Creative Commons Attribution. Download (1MB) | Preview

Abstract

Lung cancer is the commonest cause of cancer-related deaths, and current treatment involves the use of cytotoxic drugs which have many unwanted side-effects. Resveratrol, a natural polyphenol, has promising anticancer efficacy, but its therapeutic application is hindered by low bioavailability, which this study sought to improve through encapsulation into nanoparticles (NPs).Resveratrol was loaded into poly(glycerol adipate-co-ω-pentadecalactone) (PGA-co-PDL; MWt 16.5 KDa) NPs with sizes between 220-230 nm, and tested against Calu-3 human lung cancer cells.

Key findings
5% and 10% resveratrol nanoparticles (RNPs) had a high encapsulation efficiency of 78 ± 0.24% and 70 ± 0.89% and a drug loading of 39 ± 0.12 µg and 70 ± 0.89 µg (w/w), respectively. The PGA-co-PDL blank NP (BNP) at 1 mg/mL had good cytocompatibility when Calu-3 cells were exposed to it for 24 h (cell viability of 87.5±4.7%). Remarkably, the 5% RNP and 10% RNP lowered, up to 80%, the IC50 for 24 h cytotoxicity of resveratrol against the cells, from 158 ± 16 µM to 32 ± 10 µM and 70 ± 13 µM, respectively.

Conclusions
Loading of resveratrol into PGA-co-PDL NPs increases its anticancer potency, thus enhancing its prospect for treating lung cancer.

Item Type:	Article
Subjects:	R Medicine > RS Pharmacy and materia medica
Divisions:	Pharmacy & Biomolecular Sciences
Publisher:	Oxford University Press (OUP)
SWORD Depositor:	A Symplectic
Date Deposited:	15 Nov 2022 16:44
Last Modified:	30 Jan 2023 16:15
DOI or ID number:	10.1093/rpsppr/rqac007
URI:	https://researchonline.ljmu.ac.uk/id/eprint/18111

View Item